Elementis (LSE:ELM) is refocusing on specialty additives because management believes a narrower, higher-margin portfolio is worth more than the broader chemicals group it used to run. The FTSE 250 company completed the sale of its pharmaceutical Manufacturing Business to Associated British Foods on 2 June 2026 and said the deal repositions it as a pure-play specialty chemicals business centred on Personal Care and Coatings.
The early numbers from that sharper focus look encouraging. In half-year results published on 30 July 2026, Elementis reported Revenue of $318.2 million, organic constant-currency growth of 4.7% and an adjusted operating Margin of 23%, up 140 basis points. Adjusted Diluted Earnings per Share rose 28.8% to 8.5 cents, and Investing.com reported that the headline metrics came in ahead of analyst estimates.
The group is also returning cash. Proceeds from the pharma sale are funding a buyback of about $35 million, and the company has been announcing purchases of its own shares almost every week since, most recently on 21 September 2026.
From Broad Chemicals Group to Additives Specialist
Elementis makes rheology modifiers and performance additives: ingredients that control how a product flows, thickens or behaves. Its Personal Care arm supplies rheology modifiers and antiperspirant actives for cosmetics and toiletries, while Coatings sells rheology modifiers and performance additives into decorative and industrial paints.
Chief executive Luc van Ravenstein summed up the model on the results call, saying additives make up "typically one to 2%" of a formulation but are "critical for performance". Customers rarely switch a small but vital ingredient on price alone, which helps explain why specialty additive makers can earn higher margins than Commodity chemical producers.
The pharma exit continues a longer process of pruning. On the half-year call, management pointed to earlier divestments of its talc and chromium operations. Together these disposals leave a smaller group that should, in management's view, be less Capital intensive and more profitable per dollar of sales.
Inside the Half-Year Numbers
Both remaining divisions grew in the six months to 30 June 2026, according to the results summary reported by Investing.com. Coatings was the larger contributor, with revenue of $209.0 million, organic growth of 5.6% and adjusted operating profit of $43.2 million. Its margin rose 250 basis points to 20.7%.
Personal Care posted revenue of $109.2 million, organic growth of 2.9% and adjusted operating profit of $41.6 million. Its margin edged up 30 basis points to 38.1%, making it the group's most profitable division by some distance.
Group adjusted operating profit was $73.2 million. Net debt, excluding pensions and leases, stood at $163.8 million, or 1.1 times earnings before interest, tax, Depreciation and amortisation. That is close to the group's Leverage target of about 1.0 times.
Innovation, Buybacks and the Dividend
Management wants innovation to drive growth, not just cost cuts. On the call, it said revenue from its hectorite-based skincare ingredients rose 12%, supported by more than 800 new customer product launches. CHARGUARD, a fire-protection additive for wire and cable, generated $1.5 million of revenue in the half: small for now, but an example of the new applications the company is chasing.
The Alchemy acquisition, completed in November 2025, was described on the call as delivering sustainable double-digit growth. Bolt-on deals of this kind fit a strategy of adding technology to the core additives platform rather than expanding into unrelated areas.
Shareholder returns are rising too. The board declared an interim Dividend of 1.5 US cents per share, up 15.4% on the prior year. Buybacks in the first half totalled $6.7 million, of which $4.1 million came from the programme that began in June 2026.
Targets That Set the Bar
Elementis (LSE:ELM) has set out medium-term goals that give investors a way to judge progress. These include mid-single-digit organic growth through the cycle, an adjusted Operating Margin of 23% or more, and three-year operating cash conversion above 90%. It also targets return on capital employed above 30% and net Debt of around 1.0 times EBITDA.
The first-half margin of 23% means the group is already at the bottom of its margin target. The harder test is sustaining that level across a full year and through weaker demand, when Volume declines can quickly erode the benefit of a leaner cost base.
For 2026 as a whole, management said it expects full-year adjusted operating profit to be in line with market expectations, which Investing.com put at $135.2 million. It also pointed to a strong third-quarter order book, although that is company commentary rather than a guarantee of results.
Risks on the Road
Raw material costs remain a live issue. Management referred to "inflationary impacts of the Middle East war" on input costs and said it was offsetting them through pricing. If costs rise faster than prices can be passed on, margins could come under pressure.
Demand is another watchpoint. Coatings depends in part on decorative and industrial paint volumes, which tend to track housing, construction and industrial activity. Management flagged possible effects of the Middle East conflict on Demand and Supply chains as well as costs.
The portfolio is also now more concentrated. With two main divisions, a setback in either has a bigger effect on group earnings than it would have done in the old, wider business. Currency movements add a further layer, as Elementis reports in US dollars while its shares trade in pence.
What to Watch Next
The buyback is the most visible near-term activity, with weekly transaction reports showing how quickly the roughly $35 million programme is being deployed. Investors will also watch whether the third-quarter order strength management described turns into second-half revenue and margins.
Board changes are also in focus. On 16 September 2026, Elementis announced the appointment of a new Senior Independent Director, one of the governance roles that matters most when shareholders assess a board's oversight.
Full-year results will show whether the 23% margin can hold for a whole year and how much of the pharma proceeds have been returned. Elementis's shift to specialty additives now has early evidence behind it; the next few reporting periods will show whether that performance lasts through a full economic cycle.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...